Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | President | September 09, 2020 | September 11, 2020 |
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | Director | June 02, 2021 | June 04, 2021 |
| BCLS Acquisition Corp.BLSA · Entity 145747 | Director | October 22, 2020 | October 22, 2020 |
| CITY THERAPEUTICS, INC.CTY · Entity 184066 | Director | October 15, 2026 | October 16, 2026 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director | June 22, 2026 | June 23, 2026 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date September 09, 2020 · Filed September 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,412 |
Reported balance
After 2020-07-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-07-16 · Gift · Acquired 3,176 · Balance 65,412 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Common StockSEC Table I · non-derivative | Direct | 114,873 |
Reported balance
After 2020-09-09 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-09-09 · Exercise / conversion · Acquired 44,530 · Balance 114,873 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 100,798 |
Reported balance
After 2020-09-09 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2020-09-09 · Sale · Disposed 14,075 · Balance 100,798 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F3: Sale prices ranged from $122.00 to $123.00. |
| Common StockSEC Table I · non-derivative | Direct | 73,689 |
Reported balance
After 2020-09-09 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2020-09-09 · Sale · Disposed 27,109 · Balance 73,689 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F4: Sale prices ranged from $123.01 to $124.00. |
| Common StockSEC Table I · non-derivative | Direct | 70,343 |
Reported balance
After 2020-09-09 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2020-09-09 · Sale · Disposed 3,346 · Balance 70,343 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F5: Sale prices ranged from $124.03 to $124.87. |
| Common StockSEC Table I · non-derivative | Indirectby Dependent | 155 |
Reported balance
After 2020-07-16 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2020-07-16 · Gift · Acquired 155 · Balance 155 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 3,331 |
Reported balance
After 2020-07-16 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2020-07-16 · Gift · Disposed 155 · Balance 3,331 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 3,176 |
Reported balance
After 2020-07-16 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2020-07-16 · Gift · Disposed 155 · Balance 3,176 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 0 |
Reported balance
After 2020-07-16 transaction · row 9
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 9 · 2020-07-16 · Gift · Disposed 3,176 · Balance 0 F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.14 · Expires 2020-12-08 | Direct | 0 |
Reported balance
After 2020-09-09 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-09-09 · Exercise / conversion · Disposed 44,530 · Balance 0 F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F7: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 3,003 |
Reported balance
Holding disclosure · report date 2020-09-09 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 3,003 F6: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person.
F2: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020.
F3: Sale prices ranged from $122.00 to $123.00.
F4: Sale prices ranged from $123.01 to $124.00.
F5: Sale prices ranged from $124.03 to $124.87.
F6: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F7: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.
Acorda Therapeutics, Inc.
Report date June 02, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2031-06-02 | Direct | 10,000 |
Reported balance
After 2021-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 2, 2021, with the first quarterly installment vesting on September 2, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 2, 2021, with the first quarterly installment vesting on September 2, 2021.
BCLS Acquisition Corp.
Report date October 22, 2020 · Filed October 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249284) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249284) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
CITY THERAPEUTICS, INC.
Report date October 15, 2026 · Filed October 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.92 · Expires 2034-09-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares underlying this option vest in 48 equal monthly installments following September 29, 2024, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in 48 equal monthly installments following September 29, 2024, subject to the Reporting Person's continued service on each such vesting date.
Dyne Therapeutics, Inc.
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.87 · Expires 2036-06-21 | Direct | 57,463 |
Reported balance
After 2026-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 57,463 · Balance 57,463 F1: The option was granted on June 22, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments through June 22, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 22, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments through June 22, 2029.
Karyopharm Therapeutics Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,415 |
Reported balance
After 2026-05-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 15,508 · Balance 16,415 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event. F2: Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.
F2: Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sage Therapeutics, Inc.
Report date July 31, 2025 · Filed July 31, 2025
Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-07-31 · Other · Disposed 46,940 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2025-07-31 · Disposition to issuer · Disposed 53,229 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.97 · Expires 2035-01-16 | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-31 · Disposition to issuer · Disposed 174,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes.
F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 23, 2026 20:07 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 57,463 | $0.00 Strike: $20.87 | $0.00 |
DisclosureSEC source: 0001291963-26-000008 · ownership.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,463 Underlying: Common Stock · 57,463 shares Expires 2036-06-21 F1 · derivative.exercise_date: The option was granted on June 22, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments through June 22, 2029. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 15,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001291963-26-000004 · ownership.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,415 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event. F2 · balance_after: Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025. Read SEC document |
| July 31, 2025 Filed Jul 31, 2025 15:17 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Disposition to issuerStock Option (Right to Buy) · Derivative | 174,000 | Not disclosed Strike: $6.97 | Not disclosed |
DisclosureSEC source: 0000950170-25-100636 · ownership.xml · derivative · entry 3 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 174,000 shares Expires 2035-01-16 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 31, 2025 Filed Jul 31, 2025 15:17 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Disposition to issuerCommon Stock | 53,229 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-100636 · ownership.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2 · kind: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2 · price: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. Read SEC document |
| July 31, 2025 Filed Jul 31, 2025 15:17 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | OtherCommon Stock | 46,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-100636 · ownership.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2 · kind: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2 · price: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. Read SEC document |
| May 28, 2025 Filed May 29, 2025 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 4,600 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0000950170-25-078944 · ownership.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires 2035-05-27 F1 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F1 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 28, 2026. F1 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F1 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:09 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Tax withholdingCommon Stock | 4,862 | $6.91 | $33,596.42 |
DisclosureSEC source: 0001562180-25-003112 · primarydocument.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,169 Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:09 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantCommon Stock | 19,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003112 · primarydocument.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,031 F1 · shares: On February 11, 2022, the reporting person was granted Performance Restricted Stock Units (PSUs) to acquire a total of 57,040 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on April 10, 2025, resulting in the vesting of the PSUs as to 19,964 shares. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 21:11 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 174,000 | $0.00 Strike: $6.97 | $0.00 |
DisclosureSEC source: 0001562180-25-000437 · primarydocument.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,000 Underlying: Common Stock · 174,000 shares Expires 2035-01-16 F1 · derivative.exercise_date: The securities awarded on January 16, 2025 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. Options to purchase 43,500 shares of common stock shall vest on the one year anniversary of January 16, 2025, with 130,500 shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:05 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Tax withholdingCommon Stock | 12,273 | $8.96 | $109,966.08 |
DisclosureSEC source: 0001562180-24-006090 · primarydocument.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,067 Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:05 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantCommon Stock | 50,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-006090 · primarydocument.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,340 F1 · shares: On February 13, 2024, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 126,000 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on August 5, 2024, resulting in the vesting of the PSUs as to 50,400 shares. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:25 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000950170-24-066781 · ownership.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 29, 2025. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:02 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 168,000 | $0.00 Strike: $23.02 | $0.00 |
DisclosureSEC source: 0001562180-24-001336 · primarydocument.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,000 Underlying: Common Stock · 168,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: The securities awarded on February 13, 2024 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 42,000 shares of common stock shall vest on the one year anniversary of February 13, 2024, with 126,000 shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:15 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $85.82 | $0.00 |
DisclosureSEC source: 0001562180-23-006237 · primarydocument.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: On January 4, 2021, the reporting person was granted an option to purchase 650,000 shares of common stock. The option vests upon the achievement of certain milestones, one of which was met on August 4, 2023, resulting in the vesting of the option as to 195,000 shares. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-23-032137 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 24, 2024. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:46 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 66,500 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001562180-23-001422 · primarydocument.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 66,500 shares Expires 2033-02-13 F1 · derivative.exercise_date: The securities awarded on February 13, 2023 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 16,625 shares of common stock shall vest on the one year anniversary of February 13, 2023, with 49,875 shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 21:04 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | PurchaseCommon Stock | 14,500 | $34.48 | $500,022.35 |
DisclosureSEC source: 0001562180-22-007667 · primarydocument.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,940 F1 · price: This transaction was executed in multiple trades at prices ranging from $34.19 USD to $34.86 USD. The price reported above reflects the weighted average purchase price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 12:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 7,576 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001209191-22-045718 · doc4.xml · derivative · entry 2 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,576 shares Expires 2023-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 14, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 12:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 7,576 | $1.49 | $11,250.36 |
DisclosureSEC source: 0001209191-22-045718 · doc4.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2022 Filed May 20, 2022 20:02 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0001209191-22-030953 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2032-05-18 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:42 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 69,920 | $0.00 Strike: $43.04 | $0.00 |
DisclosureSEC source: 0001562180-22-001477 · primarydocument.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,920 Underlying: Common Stock · 69,920 shares Expires 2032-02-11 F1 · derivative.exercise_date: The securities awarded on February 11, 2022 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 17,480 shares of common stock shall vest on the one year anniversary of February 11, 2022, with 52,440 shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 13:07 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | PurchaseCommon Stock | 23,640 | $43.15 | $1,020,054.18 |
DisclosureSEC source: 0001562180-21-005226 · primarydocument.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,440 F1 · price: This transaction was executed in multiple trades at prices ranging from $42.66 USD to $43.46 USD. The price reported above reflects the weighted average purchase price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 13:14 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | PurchaseCommon Stock | 8,800 | $56.32 | $495,627.44 |
DisclosureSEC source: 0001562180-21-004342 · primarydocument.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 F1 · price: This transaction was executed in multiple trades at prices ranging from $56.12 USD to $56.41 USD. The price reported above reflects the weighted average purchase price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 07:11 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 10,000 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001209191-21-038106 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 2, 2021, with the first quarterly installment vesting on September 2, 2021. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:33 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001209191-21-035026 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2031-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the "Issuer"), provided that the reporting person continues to serve as a director of the Issuer through such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:22 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Options (Right to buy) · Derivative | 390,000 | $0.00 Strike: $85.82 | $0.00 |
DisclosureSEC source: 0001562180-21-000188 · primarydocument.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: The securities awarded on January 4, 2021 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 97,500 shares of common stock shall vest on the one year anniversary of January 4, 2021, with 292,500 shares vesting in 36 equal monthly installments thereafter, so long as the Reporting Person remains an employee or consultant of the Company on each of the applicable vesting dates. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:43 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Options (Right to buy) · Derivative | 20,000 | $0.00 Strike: $59.53 | $0.00 |
DisclosureSEC source: 0001562180-20-006284 · primarydocument.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-10-01 F1 · derivative.exercise_date: All of the shares subject to the option vest in equal monthly installments during the 36 months following October 1, 2020 (the "Grant Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date, subject to the reporting person's continued service as a director of the issuer through such date. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 44,530 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001735276-20-000098 · edgardoc.xml · derivative · entry 11 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,530 shares Expires 2020-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F7 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 3,346 | $124.38 | $416,175.48 |
DisclosureSEC source: 0001735276-20-000098 · edgardoc.xml · nonDerivative · entry 5 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,343 F2 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F5 · price: Sale prices ranged from $124.03 to $124.87. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 27,109 | $123.39 | $3,344,979.51 |
DisclosureSEC source: 0001735276-20-000098 · edgardoc.xml · nonDerivative · entry 4 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,689 F2 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F4 · price: Sale prices ranged from $123.01 to $124.00. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 14,075 | $122.66 | $1,726,439.50 |
DisclosureSEC source: 0001735276-20-000098 · edgardoc.xml · nonDerivative · entry 3 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,798 F2 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. F3 · price: Sale prices ranged from $122.00 to $123.00. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 44,530 | $9.14 | $407,004.20 |
DisclosureSEC source: 0001735276-20-000098 · edgardoc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 1,036 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001735276-20-000093 · edgardoc.xml · derivative · entry 10 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,589 Underlying: Common Stock · 1,036 shares Expires 2024-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 1,124 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-20-000093 · edgardoc.xml · derivative · entry 9 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,876 Underlying: Common Stock · 1,124 shares Expires 2025-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 1,587 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001735276-20-000093 · edgardoc.xml · derivative · entry 8 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,413 Underlying: Common Stock · 1,587 shares Expires 2023-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 1,184 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-20-000093 · edgardoc.xml · derivative · entry 7 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,816 Underlying: Common Stock · 1,184 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,184 | $42.22 | $49,988.48 |
DisclosureSEC source: 0001735276-20-000093 · edgardoc.xml · nonDerivative · entry 4 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,124 | $88.95 | $99,979.80 |
DisclosureSEC source: 0001735276-20-000093 · edgardoc.xml · nonDerivative · entry 3 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,036 | $96.45 | $99,922.20 |
DisclosureSEC source: 0001735276-20-000093 · edgardoc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,587 | $63.00 | $99,981.00 |
DisclosureSEC source: 0001735276-20-000093 · edgardoc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2020 Filed Sep 11, 2020 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GiftCommon Stock | 3,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-20-000098 · edgardoc.xml · nonDerivative · entry 9 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. Read SEC document |
| July 16, 2020 Filed Sep 11, 2020 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GiftCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-20-000098 · edgardoc.xml · nonDerivative · entry 8 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 3,176 F1 · kind: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. Read SEC document |
| July 16, 2020 Filed Sep 11, 2020 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GiftCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-20-000098 · edgardoc.xml · nonDerivative · entry 7 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 3,331 F1 · kind: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. Read SEC document |
| July 16, 2020 Filed Sep 11, 2020 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GiftCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-20-000098 · edgardoc.xml · nonDerivative · entry 6 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Dependent Disclosed balance after: 155 F1 · kind: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. Read SEC document |
| July 16, 2020 Filed Sep 11, 2020 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GiftCommon Stock | 3,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-20-000098 · edgardoc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,412 F1 · kind: Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 22,265 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001735276-20-000084 · edgardoc.xml · derivative · entry 5 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,530 Underlying: Common Stock · 22,265 shares Expires 2020-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020. F4 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 22,265 | $159.99 | $3,562,177.35 |
DisclosureSEC source: 0001735276-20-000084 · edgardoc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,236 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 22,265 | $9.14 | $203,502.10 |
DisclosureSEC source: 0001735276-20-000084 · edgardoc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 16:55 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 15,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001209191-20-037298 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 15, 2020, with the first quarterly installment vesting on September 15, 2020. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 16,400 | $0.00 Strike: $19.11 | $0.00 |
DisclosureSEC source: 0001209191-20-032007 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2030-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 21, 2021, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.